{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:01:20Z","timestamp":1785402080258,"version":"3.56.0"},"reference-count":27,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011576","name":"\u0130n\u00f6n\u00fc University Scientific Research Projects Coordination Unit","doi-asserted-by":"publisher","award":["TSA-2026-4756"],"award-info":[{"award-number":["TSA-2026-4756"]}],"id":[{"id":"10.13039\/501100011576","id-type":"DOI","asserted-by":"publisher"}]},{"award":["TSA-2026-4756"],"award-info":[{"award-number":["TSA-2026-4756"]}],"id":[{"id":"https:\/\/ror.org\/04asck240","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Polypharmacy is highly prevalent among older adults with type 2 diabetes mellitus (T2DM) and is traditionally considered a marker of geriatric vulnerability. However, it remains unclear whether polypharmacy is more closely associated with multidimensional frailty or metabolic burden in this population. Methods: In this retrospective cross-sectional study, 278 adults aged \u226565 years with T2DM underwent comprehensive geriatric assessment (CGA), including evaluation of functional status, cognition, nutrition, depressive symptoms, frailty, and physical performance. Frailty was assessed using the Fried phenotype. Polypharmacy was defined as the concurrent use of \u22655 medications. Multivariable logistic regression and interaction analyses were performed to identify independent predictors of polypharmacy. Receiver operating characteristic (ROC) analyses were conducted to evaluate the discriminative performance of metabolic parameters. Results: Polypharmacy was present in 54.7% of participants. Patients with polypharmacy had significantly higher HbA1c and fasting glucose levels compared with those without polypharmacy (both p &lt; 0.001). In multivariable analysis, higher HbA1c levels remained independently associated with polypharmacy (OR = 4.99, 95% CI: 3.18\u20137.84, p &lt; 0.001), whereas frailty status was not significantly associated with polypharmacy (OR = 0.58, 95% CI: 0.15\u20132.21, p = 0.427). No significant interaction was observed between HbA1c and frailty status (p for interaction &gt; 0.05). Among CGA domains, only functional status and gait speed differed in unadjusted analyses, while cognition, nutritional status, and depressive symptoms were not significantly associated with polypharmacy after adjustment. HbA1c demonstrated strong discriminative performance for polypharmacy (AUC = 0.898, 95% CI: 0.863\u20130.931), with an optimal cut-off of 6.81%. Conclusions: In older adults with T2DM, polypharmacy appeared to be more closely associated with markers of poor glycemic control, particularly HbA1c levels, than with frailty status itself. These findings suggest that medication burden in older adults with T2DM may reflect treatment intensification and suboptimal glycemic control in addition to geriatric vulnerability.<\/jats:p>","DOI":"10.3390\/jcm15124674","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:27:21Z","timestamp":1781666841000},"page":"4674","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polypharmacy Reflects Metabolic Burden Rather than Frailty in Older Adults with Type 2 Diabetes: A Comprehensive Geriatric Assessment Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5633-0939","authenticated-orcid":false,"given":"Funda Datl\u0131","family":"Yakary\u0131lmaz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Geriatrics, Faculty of Medicine, \u0130n\u00f6n\u00fc University, Malatya 44280, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6131-0390","authenticated-orcid":false,"given":"Ayten","family":"Erayd\u0131n","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Pamukkale University, Denizli 20070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","article-title":"An update on the clinical consequences of polypharmacy in older adults: A narrative review","volume":"17","author":"Wastesson","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1016\/S2666-7568(24)00007-2","article-title":"Prevalence of multimorbidity and polypharmacy among adults and older adults: A systematic review","volume":"5","author":"Nicholson","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2019). 12. Older Adults: Standards of Medical Care in Diabetes-2019. Diabetes Care, 42, S139\u2013S147.","DOI":"10.2337\/dc19-S012"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jama.2016.0299","article-title":"Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults with Type 2 Diabetes","volume":"315","author":"Lipska","year":"2016","journal-title":"JAMA"},{"key":"ref_6","first-page":"16","article-title":"Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1111\/j.1532-5415.2005.53501.x","article-title":"Prognostic value of usual gait speed in well-functioning older people--results from the Health, Aging and Body Composition Study","volume":"53","author":"Cesari","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_8","first-page":"456\u2013463; discussion 463\u2013465","article-title":"Overview of the MNA. Its history and challenges","volume":"10","author":"Vellas","year":"2006","journal-title":"J. Nutr. Health Aging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: Evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/bcp.13590","article-title":"The relationship between frailty and polypharmacy in older people: A systematic review","volume":"84","author":"Izquierdo","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101811","DOI":"10.1016\/j.arr.2022.101811","article-title":"Prevalence and health outcomes of polypharmacy and hyperpolypharmacy in older adults with frailty: A systematic review and meta-analysis","volume":"83","author":"Toh","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1748-3743.2007.00074.x","article-title":"A comparative review of the Katz ADL and the Barthel Index in assessing the activities of daily living of older people","volume":"2","author":"Hartigan","year":"2007","journal-title":"Int. J. Older People Nurs."},{"key":"ref_13","first-page":"87\u201394; discussion 143\u2013150","article-title":"A guide to the standardized Mini-Mental State Examination","volume":"9","author":"Molloy","year":"1997","journal-title":"Int. Psychogeriatr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: A preliminary report","volume":"17","author":"Yesavage","year":"1982","journal-title":"J. Psychiatr. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rubenstein, L.Z., Harker, J.O., Salv\u00e0, A., Guigoz, Y., and Vellas, B. (2001). Screening for undernutrition in geriatric practice: Developing the short-form mini-nutritional assessment (MNA-SF). J. Gerontol. A Biol. Sci. Med. Sci., 56.","DOI":"10.1093\/gerona\/56.6.M366"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2010.1923","article-title":"Gait speed and survival in older adults","volume":"305","author":"Studenski","year":"2011","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/17446651.2022.2079495","article-title":"Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age \u226560years) or frail adults with type 2 diabetes: A systematic review and meta-analysis from randomized controlled trial and observation studies","volume":"17","author":"Crabtree","year":"2022","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s40520-022-02165-1","article-title":"Prevalence and impact of polypharmacy in older patients with type 2 diabetes","volume":"34","author":"Remelli","year":"2022","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care, 48, S181\u2013S206.","DOI":"10.2337\/dc25-S009"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jdiacomp.2017.05.003","article-title":"Frailty and sarcopenia\u2014Newly emerging and high impact complications of diabetes","volume":"31","author":"Sinclair","year":"2017","journal-title":"J. Diabetes Complicat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.2337\/dc06-1058","article-title":"The burden and treatment of diabetes in elderly individuals in the U.S","volume":"29","author":"Selvin","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026). 13. Older Adults: Standards of Care in Diabetes-2026. Diabetes Care, 49, S277\u2013S296.","DOI":"10.2337\/dc26-S013"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Abd Ghafar, M.Z.A., O\u2019Donovan, M., Sezgin, D., Moloney, E., Rodr\u00edguez-Laso, \u00c1., Liew, A., and O\u2019Caoimh, R. (2022). Frailty and diabetes in older adults: Overview of current controversies and challenges in clinical practice. Front. Clin. Diabetes Healthc., 3.","DOI":"10.3389\/fcdhc.2022.895313"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s41999-018-0124-5","article-title":"Association of polypharmacy and hyperpolypharmacy with frailty states: A systematic review and meta-analysis","volume":"10","author":"Palmer","year":"2019","journal-title":"Eur. Geriatr. Med."},{"key":"ref_25","first-page":"259","article-title":"Polypharmacy and frailty: Prevalence, relationship, and impact on mortality in older adults","volume":"16","author":"Herr","year":"2015","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ecl.2013.02.010","article-title":"Diabetes and altered glucose metabolism with aging","volume":"42","author":"Kalyani","year":"2013","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e020852","DOI":"10.1136\/bmjopen-2017-020852","article-title":"Polypharmacy among patients with diabetes: A cross-sectional retrospective study in a tertiary hospital in Saudi Arabia","volume":"8","author":"Alwhaibi","year":"2018","journal-title":"BMJ Open"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4674\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:17:43Z","timestamp":1781669863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15124674"],"URL":"https:\/\/doi.org\/10.3390\/jcm15124674","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}